Funan Huang
Bayer (United States)(US)Whipps Cross University Hospital(GB)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, Chronic Lymphocytic Leukemia Research, HER2/EGFR in Cancer Research, Colorectal Cancer Treatments and Studies, Biosimilars and Bioanalytical Methods
Most-Cited Works
- → 227 Th-Labeled Anti-CD22 Antibody (BAY 1862864) in Relapsed/Refractory CD22-Positive Non-Hodgkin Lymphoma: A First-in-Human, Phase I Study(2021)28 cited
- → Clinical Pharmacokinetics of the Androgen Receptor Inhibitor Darolutamide in Healthy Subjects and Patients with Hepatic or Renal Impairment(2021)15 cited
- → A phase 1b study evaluating the safety and pharmacokinetics of regorafenib in combination with cetuximab in patients with advanced solid tumors(2019)9 cited
- → A phase I study to determine the effect of regorafenib (REG) on the pharmacokinetics (PK) of substrates of P-glycoprotein (P-gp; digoxin) and breast cancer resistant protein (BCRP; rosuvastatin) in patients with advanced solid tumors(2016)8 cited
- → Exposure–Response Modeling and Simulation of Progression‐Free Survival and Adverse Events of Sorafenib Treatment in Patients With Advanced Thyroid Cancer(2019)7 cited
- → Phase I dose-escalation study of the pan-PI3 K inhibitor copanlisib in children and adolescents with relapsed/refractory solid tumors(2022)5 cited
- → A phase I pharmacokinetic study of copanlisib in Chinese patients with relapsed indolent non-Hodgkin lymphoma(2022)5 cited
- → Phase 1, open-label, dose-escalation study of sorafenib in combination with eribulin in patients with advanced, metastatic, or refractory solid tumors(2018)4 cited
- → OC-0507 Risk factors for bladder fistula, bleeding and cystitis in cervix cancer: an EMBRACE analysis(2019)4 cited
- → No Effect of Levothyroxine and Levothyroxine-Induced Subclinical Thyrotoxicosis on the Pharmacokinetics of Sorafenib in Healthy Male Subjects(2017)3 cited